For instance, in the context of Parkinson’s disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons, with aging as a major risk factor, research indicates that treatment with Fer-1, a ferroptosis inhibitor, reduces p53 levels while increasing the expression of ferroptosis regulators such as SLC7A11 and GPX4, thereby mitigating cellular senescence (Li et al., 2021). This evidence concerns the gene TP53 and Parkinson disease.